Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02230969 · ClinicalTrials.gov registry record
Plegridy Observational Program
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 1,208
- Enrollment target
NCT02230969: Completed study, sponsored by Biogen.
NCT02230969 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 1,208 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02230969 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 1,208 participants
- Enrollment target
Study Summary
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice. The secondary objectives of this study in this study population are to describe Plegridy prescription and utilization adherence patterns in routine clinical practice; to assess the specific long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice; to monitor the safety and tolerability of Plegridy in routine clinical practice by assessing the incidence of adverse events (AEs) of flu-like symptoms (FLS), injection site reactions (ISRs), and AEs (including laboratory abnormalities) leading to treatment discontinuation; to assess the effect of FLS on participant-reported effectiveness of, and satisfaction with, prophylactic management using a FLS-Visual Analog Scale (FLS-VAS); to evaluate the change in health-related quality of life (HRQoL), FLS, FLS-VAS, healthcare resource consumption, and treatment adherence over time.
Interventions
- DRUG peginterferon beta-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,208 participants |
| Start Date | 2014-11-12 |
| Est. Completion | 2022-01-20 |
What the finished NCT02230969 record still lists
NCT02230969 is an observational study that tracks outcomes without assigning an intervention. Its 1,208 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which peginterferon beta-1a is the first listed.
NCT02230969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02230969 about?
NCT02230969 is a clinical study titled "Plegridy Observational Program". The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms...
What is the current status of trial NCT02230969?
This trial is currently completed. The enrollment target is 1,208 participants. The study started on 2014-11-12. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT02230969?
The interventions under investigation include: peginterferon beta-1a (DRUG).
Who is sponsoring clinical trial NCT02230969?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI